A global leader in integrated solutions is looking for the following Intermediate required for their new product Synthesis and development.
(Sa)-Methyl 2-(benzyloxycarbonylamino) spiro[3.3]heptane-6- carboxylate
The quantity required is 1 kg / 10 kg / 20 kg lots.


Comments :


WE are interested in knowing more details.

10:26,  04 Dec 2018


GVK BIO offer long term Contract Manufacturing services right from strategic partnerships in development, validations, DMF filing and commercial manufacturing of Active Pharmaceutical Ingredients (APIs)/advanced intermediates to APIs
Our manufacturing facility has approvals from worldwide regulatory authorities like below and these accreditations facilitate faster and easier approvals of DMFs/dossiers for our business partners.
a) In rare instance a joint audit was performed by auditors from USFDA, EDQM and Spanish MOH in 2013.
b) We are approved by PMDA (Pharmaceutical and Medical Devices Agency) Japan in 2012 and supplying commercially to customers in Japan including Pfizer Japan.
c) FDA Korea approved us in 2012, we have our presence for a decade in Korea market and we serve to almost 8-9 OEMs.
USFDA in 2015 & 2018 (Received EIR)

11:03,  04 Dec 2018


We can help you out regarding this. Please contact us at tvkannan@molclonelabs.com.

12:58,  04 Dec 2018

PharmaCompass – Grow Your Pharma Business Digitally. What is Telmisartan? Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.